DOCSLIB.ORG

Spontaneous Risperidone Dosage Is Related to CYP2D6, CYP3A5 and ABCB1 Genotypes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Spontaneous Risperidone Dosage Is Related to CYP2D6, CYP3A5 and ABCB1 Genotypes The Pharmacogenomics Journal (2012) 12, 255–259 & 2012 Macmillan Publishers Limited. All rights reserved 1470-269X/12 www.nature.com/tpj ORIGINAL ARTICLE Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes S Mas1,2,3, P Gasso` 1,2,3, The aim of this study is to evaluate whether the quantitative prescription of ´ 1,2,3 4,2,3 risperidone (dosage) is related to the patient’s metabolic status. Metabolic SAlvarez , E Parellada , status was defined in terms of the most relevant polymorphisms of CYP2D6 4,5,2,3 M Bernardo and (*3, *4, *5, *6 and *1xN), CYP3A5 (*3A) and ABCB1 (G2677T) determined a A Lafuente1,2,3 posteriori and blinded to the clinicians. This prospective and observational study includes a cohort of 151 Caucasian psychiatric patients treated with 1Department of Pathological Anatomy, risperidone. Significant differences (Kruskal–Wallis test p ¼ 0.01) among the Pharmacology and Microbiology, University of doses administered were observed to correlate (Spearman’s r ¼ 1, p ¼ 0.02) Barcelona, Barcelona, Spain; 2Institut d’Investigacions Biome´diques August Pi i Sunyer with the different CYP2D6 groups. Poor metabolizers received the lowest (IDIBAPS), Barcelona, Spain; 3Centro de doses and ultra rapid metabolizers the highest. No significant correlations Investigacio´n Biome´dica en Red de Salud Mental were observed with regard to CYP3A5 and ABCB1. We find that, despite not 4 (CIBERSAM), Barcelona, Spain; Psychiatry knowing patients’ metabolic status, clinicians modify risperidone dosage in service, Hospital Clinic de Barcelona, Barcelona, Spain and 5Department of Psychiatry order to obtain the best therapeutic option. and Clinical Psychobiology, University of The Pharmacogenomics Journal (2012) 12, 255–259; doi:10.1038/tpj.2010.91; Barcelona, Barcelona, Spain published online 21 December 2010 Correspondence: Keywords: pharmacogenetics; risperidone; CYP2D6; CYP3A5; ABCB1; dose titration Dr A Lafuente, Department of Pathological Anatomy, Pharmacology and Microbiology, University of Barcelona, IDIBAPS, Casanova 143, E-08036 Barcelona, Spain. E-mail: [email protected] Introduction One of the most important issues regarding the variability of effect of antipsychotic drugs (AP) is the consequences of genetic variation in the regulators of drug metabolism. Concerning the metabolism of AP, the main metabolic pathway for many typical AP is CYP2D6, whereas for atypical AP, the most important CYPs are CYP3A4/A5, CYP2D6 and CYP1A2. CYP2D6 represents an average of 2% of hepatic CYP content and it is one of the best-known polymorphic drug-metabolizing enzymes with over 75 function- ally important allelic variants of CYP2D6 described to date (http://www.imm.ki. se/cypalleles). The CYP3A family, including CYP3A4, CYP3A5, CYP3A7 and CYP3A43, exhibits broad substrate specificity and metabolizes more than 50% of all pharmaceutical drugs.1 The CYP3A5 protein is polymorphically expressed in the liver and intestines, and several genetic variants have been identified (http:// www.imm.ki.se/cypalleles). Individuals with deficient CYP enzyme activity are classified as poor metabolizers (PM) and carry two detrimental CYP alleles. Individuals with slightly subnormal or normal rates of metabolism are defined as either intermediate metabolizers (IM; with only one functional copy) or Received 6 August 2010; revised 20 October 2010; accepted 16 November 2010; published extensive metabolizers (EM; with two functional copies of the gene), respectively. online 21 December 2010 Intermediate metabolizers have higher median metabolic ratios than homozygous Risperidone intuitive pharmacogenetics S Mas et al 256 EM. For CYP2D6, in addition, a subgroup of ultrarapid Hospital Clı´nic (Barcelona, Spain) over a period of 3 years metabolizers (UM) with extremely high enzyme activity can (2002À2004). In total, 151 subjects from this cohort be identified. (diagnosed following the DSM-IV criteria) treated with Risperidone is a widely used atypical AP for the treatment risperidone participated in this retrospective and observa- of schizophrenia and other psychotic disorders. It is tional study. A full description of this population can be extensively metabolized in the liver to a pharmacologically found in previous studies.12–16 active metabolite, 9-hydroxyrisperidone, mainly by cyto- chrome P450 2D6 (CYP2D6) and 3A (CYP3A4/3A5).2–4 Sample preparation and genotyping The antipsychotic effect of risperidone is assumed to The CYP2D6*3, *4, *5 and *6 genotypes were available for be related to the active moiety (the sum of risperidone most of the patients from previous studies.12 The newly and 9-hydroxyrisperidone), of which 9-hydroxyrisperidone included patients were genotyped using the methods constitutes the major part in plasma.5 Many in vivo and described previously.17 in vitro studies have revealed that CYP2D6 is primarily The CYP2D6 gene duplications (*1 Â N) were genotyped involved in risperidone metabolism.4 Polymorphic variants using TaqMan Copy Number Assays (assay ID Hs00010001_cn, of CYP2D6 have been shown to influence risperidone and Applied Biosystems, Foster City, CA, USA). 9-hydroxyrisperidone levels, although not the active moiety.6 The CYP3A5*3 allele and the ABCB1 (G2677T) poly- Several reports have recently suggested that CYP3A may be morphism were detected with real-time PCR by TaqMan substantially involved in the metabolism of risperidone.2 allelic discrimination pre-designed assays from Applied Bio- A polymorphic variant, CYP3A5*3, has been shown to systems according to the manufacturer’s guidelines (assay ID modulate the risperidone, 9-hydroxyrisperidone and active C__26201809_30 and C_11711720C_30, Applied Biosystems). moiety levels.6 Besides the P450 metabolizing enzymes, drug transporters Statistics are believed to affect risperidone pharmacokinetics. Data were analyzed using SPSS14.05 (statistical analysis P-glycoprotein is a member of the adenosine triphosphate- software, SPSS Inc., Chicago, IL, USA). Two-tailed P-values binding cassette (ABC) superfamily of transport proteins, o0.05 were considered to be of statistical significance. functioning as an efflux pump involved in drug absorption Means and s.d. were computed for continuous variables. and elimination.7 It has been reported that risperidone is Variables showing no normal distribution according to the a substrate of P-glycoprotein.8 Although it has not been Shapiro–Wilk test were compared with a non-parametric test studied in humans, it has been demonstrated in rats (Mann–Whitney U-test or Kruskal–Wallis test) and Spear- that risperidone crosses the blood–brain barrier more man’s rank correlation coefficients. Hardy–Weinberg equili- efficiently than 9-hydroxyrisperidone because of the effects brium and linkage disequilibrium analysis were performed of P-glycoprotein transport.9 Thus, P-glycoprotein seems to with the genetics package of the statistical software R (version pump 9-hydroxyrisperidone out of the brain more readily 2.4.0, www.r-project.org). than it pumps risperidone out. This may explain why plasma risperidone is more toxic than comparable plasma Results levels of 9-hydroxyrisperidone, even though they have similar affinities for the D2 receptor.10 A recent study The demographic and clinical characteristics of the patients showed that ABCB1 polymorphisms have a moderate effect are summarized in Table 1. The frequencies of the various on 9-hydroxyrisperidone and active moiety levels.11 metabolic phenotypes based on genotype categories According to our hypothesis, in an intuitive pharmaco- (CYP2D6 UM, EM, IM and PM; CYP3A5 EM, IM and PM) genetic exercise, clinicians (who are unaware of the patient’s and polymorphisms (ABCB1 (G2677T)) studied are also metabolic genotype) modify AP dosage via a trial and error shown in Table 1. All the polymorphisms analyzed were in strategy, in order to obtain the safest and most efficient Hardy–Weinberg equilibrium in cases and controls (data not treatment, and this will correspond with the patient’s shown). metabolic status. The aim of this study is to evaluate Figure 1 shows the mean daily dosage of risperidone in the whether the quantitative prescription of risperidone (do- different CYP2D6 (Figure 1a) and CYP3A5 (Figure 1b) sage) is related to the patient’s metabolic status (considering metabolic phenotypes. Significant differences among (Kruskal– the most relevant polymorphisms of CYP2D6 (*3, *4, *5, *6 Wallis test P ¼ 0.01) and correlation with (Spearman’s r ¼ 1, and *1xN), CYP3A5 (*3A) and ABCB1 (G2677T)), keeping in P ¼ 0.02) the dosage administered to the different CYP2D6 mind that genotyping was performed a posteriori as a part of groups were observed, with UM receiving the highest independent pharmacogenetic studies. risperidone dosage (8.8±5 mg per day, n ¼ 8), followed by EM (7.4±3 mg per day, n ¼ 90), IM (6.5±2 mg per day, n ¼ 37) and PM (5.9±2 mg per day, n ¼ 15). Post-hoc Patients and methods Bonferroni’s testing for pairwise comparisons between groups did not remain significant, probably because of the Participants small sizes of the PM and UM groups. Regarding CYP3A5, A cohort of 321 psychiatric inpatients receiving AP therapy although a trend could be observed with higher dosages for was recruited consecutively at the Psychiatry Service of the patients with higher metabolic activity (EM 7.3±3 mg per The Pharmacogenomics Journal Risperidone intuitive pharmacogenetics S Mas et al 257 Table 1 Demographic and clinical characteristics of the patients and frequencies of the various metabolic phenotypes based on the genotype categories (CYP2D6 UM, EM, IM and PM; CYP3A5 EM, IM, and PM) and polymorphisms studied (ABCB1 G2677T) N 151 Age (years, mean±s.d.) 35.9±14 Male N (%) 84 (55.6) Smokers N (%)a 59 (51.3) Diagnosis N (%) Schizophrenia and related disorders 118 (78.1) Bipolar disorders 27 (17.9) Other 6 (3.9) Risperidone dosage (mg/day, mean±s.d.) 7.2±2.5 CYP2D6 N (%)b PM 15 (9.9) IM 37 (24.5) EM 91 (60.3) UM 8 (5.3) CYP3A5 N (%)c PM 3 (2.0) IM 23 (15.5) EM 122 (82.4) ABCB1 G2677T N (%) GG 62 (41.3) GT 59 (39.3) TT 29 (19.3) Abbreviations: EM, extensive metabolizers; IM, intermediate metabolizers; PM, poor metabolizers; UM, ultrarapid metabolizers.
Load more

Recommended publications
  • 4Β-Hydroxycholesterol As Biomarker for Variation in CYP3A Activity
    ȕ-Hydroxycholesterol as biomarker for variation in CYP3A activity Dissertation for the Degree of Philosophiae Doctor (Ph.D.) Kristine Hole 2018 Center for Psychopharmacology Diakonhjemmet Hospital Oslo Department of Pharmaceutical Biosciences School of Pharmacy Faculty of Mathematics and Natural Sciences University of Oslo © Kristine Hole, 2018 Series of dissertations submitted to the Faculty of Mathematics and Natural Sciences, University of Oslo No. ISSN 1501-7710 All rights reserved. No part of this publication may be reproduced or transmitted, in any form or by any means, without permission. Cover: Hanne Baadsgaard Utigard. Print production: Reprosentralen, University of Oslo. TABLE OF CONTENTS ACKNOWLEDGEMENTS ...................................................................................................... II LIST OF PUBLICATIONS ..................................................................................................... III ABBREVIATIONS..................................................................................................................IV ABSTRACT.............................................................................................................................. V 1 INTRODUCTION.............................................................................................................. 1 1.1 Variability in drug response ....................................................................................... 1 1.2 Drug metabolism .......................................................................................................
    [Show full text]
  • Eicosanoids in Carcinogenesis
    4open 2019, 2,9 © B.L.D.M. Brücher and I.S. Jamall, Published by EDP Sciences 2019 https://doi.org/10.1051/fopen/2018008 Special issue: Disruption of homeostasis-induced signaling and crosstalk in the carcinogenesis paradigm “Epistemology of the origin of cancer” Available online at: Guest Editor: Obul R. Bandapalli www.4open-sciences.org REVIEW ARTICLE Eicosanoids in carcinogenesis Björn L.D.M. Brücher1,2,3,*, Ijaz S. Jamall1,2,4 1 Theodor-Billroth-Academy®, Germany, USA 2 INCORE, International Consortium of Research Excellence of the Theodor-Billroth-Academy®, Germany, USA 3 Department of Surgery, Carl-Thiem-Klinikum, Cottbus, Germany 4 Risk-Based Decisions Inc., Sacramento, CA, USA Received 21 March 2018, Accepted 16 December 2018 Abstract- - Inflammation is the body’s reaction to pathogenic (biological or chemical) stimuli and covers a burgeoning list of compounds and pathways that act in concert to maintain the health of the organism. Eicosanoids and related fatty acid derivatives can be formed from arachidonic acid and other polyenoic fatty acids via the cyclooxygenase and lipoxygenase pathways generating a variety of pro- and anti-inflammatory mediators, such as prostaglandins, leukotrienes, lipoxins, resolvins and others. The cytochrome P450 pathway leads to the formation of hydroxy fatty acids, such as 20-hydroxyeicosatetraenoic acid, and epoxy eicosanoids. Free radical reactions induced by reactive oxygen and/or nitrogen free radical species lead to oxygenated lipids such as isoprostanes or isolevuglandins which also exhibit pro-inflammatory activities. Eicosanoids and their metabolites play fundamental endocrine, autocrine and paracrine roles in both physiological and pathological signaling in various diseases. These molecules induce various unsaturated fatty acid dependent signaling pathways that influence crosstalk, alter cell–cell interactions, and result in a wide spectrum of cellular dysfunctions including those of the tissue microenvironment.
    [Show full text]
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Pharmacogenomic Characterization in Bipolar Spectrum Disorders
    pharmaceutics Review Pharmacogenomic Characterization in Bipolar Spectrum Disorders Stefano Fortinguerra 1,2 , Vincenzo Sorrenti 1,2,3 , Pietro Giusti 2, Morena Zusso 2 and Alessandro Buriani 1,2,* 1 Maria Paola Belloni Center for Personalized Medicine, Data Medica Group (Synlab Limited), 35131 Padova, Italy; [email protected] (S.F.); [email protected] (V.S.) 2 Department of Pharmaceutical & Pharmacological Sciences, University of Padova, 35131 Padova, Italy; [email protected] (P.G.); [email protected] (M.Z.) 3 Bendessere™ Study Center, Solgar Italia Multinutrient S.p.A., 35131 Padova, Italy * Correspondence: [email protected] Received: 25 November 2019; Accepted: 19 December 2019; Published: 21 December 2019 Abstract: The holistic approach of personalized medicine, merging clinical and molecular characteristics to tailor the diagnostic and therapeutic path to each individual, is steadily spreading in clinical practice. Psychiatric disorders represent one of the most difficult diagnostic challenges, given their frequent mixed nature and intrinsic variability, as in bipolar disorders and depression. Patients misdiagnosed as depressed are often initially prescribed serotonergic antidepressants, a treatment that can exacerbate a previously unrecognized bipolar condition. Thanks to the use of the patient’s genomic profile, it is possible to recognize such risk and at the same time characterize specific genetic assets specifically associated with bipolar spectrum disorder, as well as with the individual response to the various therapeutic options. This provides the basis for molecular diagnosis and the definition of pharmacogenomic profiles, thus guiding therapeutic choices and allowing a safer and more effective use of psychotropic drugs. Here, we report the pharmacogenomics state of the art in bipolar disorders and suggest an algorithm for therapeutic regimen choice.
    [Show full text]
  • Simulating the Impact of the Interplay Between Cyp2c19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using Pbpk-Pd Models
    SIMULATING THE IMPACT OF THE INTERPLAY BETWEEN CYP2C19 POLYMORPHISMS AND ETHNICITY ON RESPONSE TO CLOPIDOGREL, USING PBPK-PD MODELS. Manoranjenni Chetty, Khaled Abduljalil. Certara UK, Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield, United Kingdom. Background PBPK-PD Model: Lua scripting was used within the Simcyp simulator for the PBPK-PD model. A modified indirect response turnover model6, Clopidogrel is a prodrug that produces its anticoagulant effect after with maximum platelet aggregation (MPA%) as the PD marker was used conversion to Clopi-H4, the active metabolite. Clopi-H4 binds to simulate the response to Clopi-H4. % IPA was calculated as: irreversibly to the platelet P2Y12 adenosine diphosphate (ADP) % IPA = [MPApredose – MPApostdose / MPApredose] * 100% receptor, which inhibits platelet aggregation and reduces platelet Clopi-H4 concentrations from the PBPK model were used as the input to reactivity for the platelet’s life span1. the PD model. Clopidogrel is metabolized by two major metabolic pathways. An Model Performance Verification: The PBPK model was verified by esterase-dependent pathway leads to hydrolysis of clopidogrel into comparison of the predicted and clinically observed pharmacokinetic an inactive carboxylic acid derivative (85–92%) while a cytochrome parameters. P450 (CYP) dependent pathway leads to the formation of its active Following the verification of the performance of the PBPK-PD model, 2,3,4 metabolite (clopi-H4) . CYP2C19, CYP2B6, and CYP1A2 first convert simulations were repeated using healthy Chinese PM and Caucasian PM clopidogrel to the 2-oxo-clopidogrel intermediate, which is then populations. The change in % IPA was compared in the 4 groups to metabolised by esterases (about 50%) or converted to Clopi-H4 by determine the need for dosage adjustments.
    [Show full text]
  • Synonymous Single Nucleotide Polymorphisms in Human Cytochrome
    DMD Fast Forward. Published on February 9, 2009 as doi:10.1124/dmd.108.026047 DMD #26047 TITLE PAGE: A BIOINFORMATICS APPROACH FOR THE PHENOTYPE PREDICTION OF NON- SYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYTOCHROME P450S LIN-LIN WANG, YONG LI, SHU-FENG ZHOU Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191, P. R. China (LL Wang & Y Li) Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, Victoria 3083, Australia (LL Wang & SF Zhou). 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. DMD #26047 RUNNING TITLE PAGE: a) Running title: Prediction of phenotype of human CYPs. b) Author for correspondence: A/Prof. Shu-Feng Zhou, MD, PhD Discipline of Chinese Medicine, School of Health Sciences, RMIT University, WHO Collaborating Center for Traditional Medicine, Bundoora, Victoria 3083, Australia. Tel: + 61 3 9925 7794; fax: +61 3 9925 7178. Email: [email protected] c) Number of text pages: 21 Number of tables: 10 Number of figures: 2 Number of references: 40 Number of words in Abstract: 249 Number of words in Introduction: 749 Number of words in Discussion: 1459 d) Non-standard abbreviations: CYP, cytochrome P450; nsSNP, non-synonymous single nucleotide polymorphism. 2 DMD #26047 ABSTRACT Non-synonymous single nucleotide polymorphisms (nsSNPs) in coding regions that can lead to amino acid changes may cause alteration of protein function and account for susceptivity to disease. Identification of deleterious nsSNPs from tolerant nsSNPs is important for characterizing the genetic basis of human disease, assessing individual susceptibility to disease, understanding the pathogenesis of disease, identifying molecular targets for drug treatment and conducting individualized pharmacotherapy.
    [Show full text]
  • Distribution of Drug-Metabolizing Enzymes Coding Genes CYP2D6
    Turk J Biochem 2019; 44(2): 142–146 Research Article İsmail Ün*, İ. Ömer Barlas, Nisa Uyar, Bahar Taşdelen and Naci Tiftik Distribution of drug-metabolizing enzymes coding genes CYP2D6, CYP3A4, CYP3A5 alleles in a group of healthy Turkish population Bir grup sağlıklı Türk populasyonunda ilaç metabolize edici CYP2D6, CYP3A4, CYP3A5 enzimlerinin allelik dağılımı https://doi.org/10.1515/tjb-2017-0226 Conclusion: Screening of low frequency alleles by phar- Received August 16, 2017; accepted June 7, 2018; previously macogenetic testing must not be omitted to optimize published online July 9, 2018 pharmacotherapy and avoid severe drug toxicities. Fre- Abstract quency distributions of the identified polymorphisms in the present study may contribute to the personalized drug Objective: Variant alleles in specific ethnic groups are therapy regimens and prediction of possible adverse drug important for personalized drug therapy regimens and reactions in the Turkish population. adverse drug reactions. Therefore, the aim of this study Keywords: CYP2D6; CYP3A4; CYP3A5; Drug metabolism; was to investigate allelic frequencies of the CYP2D6*1, Polymorphism. CYP3A4*5, CYP3A4*18, CYP3A5*2 and CYP3A5*4 in a group of Turkish population. Materials and methods: Three hundred and six unrelated Öz healthy subjects who were accepted as blood donors to the Mersin University Blood Bank were included in Amaç: Etnik gruplardaki varyant alleller, kişiselleşti- the study after informed consent. Allelic frequencies rilmiş ilaç tedavi rejimleri ve istenmeyen ilaç reaksi- of the CYP2D6*1 (rs3892097), CYP3A4*5 (rs55901263), yonları açısından önemlidir. Bu çalışmanın amacı bir CYP3A4*18 (rs28371759), CYP3A5*2 (rs28365083) and grup Türk gönüllüde CYP2D6*1, CYP3A4*5, CYP3A4*18, CYP3A5*4 (rs56411402) were determined by using poly- CYP3A5*2 ve CYP3A5*4′ genlerinin allelik frekanslarını merase chain reaction-restriction fragment length poly- araştırmaktır.
    [Show full text]
  • Linking Premenopausal Oestrone and Progesterone Levels with Risk of Hormone Receptor-Positive Breast Cancers
    This is a repository copy of CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/170952/ Version: Published Version Article: Johnson, N, Maguire, S, Morra, A et al. (145 more authors) (2021) CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor- positive breast cancers. British Journal of Cancer, 124 (4). pp. 842-854. ISSN 0007-0920 https://doi.org/10.1038/s41416-020-01185-w Reuse This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ www.nature.com/bjc ARTICLE Epidemiology CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers Nichola Johnson et al. BACKGROUND: Epidemiological studies provide strong evidence for a role of endogenous sex hormones in the aetiology of breast cancer. The aim of this analysis was to identify genetic variants that are associated with urinary sex-hormone levels and breast cancer risk.
    [Show full text]
  • NIH Public Access Author Manuscript Pharmacogenet Genomics
    NIH Public Access Author Manuscript Pharmacogenet Genomics. Author manuscript; available in PMC 2013 August 08. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Pharmacogenet Genomics. 2012 July ; 22(7): 555–558. doi:10.1097/FPC.0b013e328351d47f. PharmGKB summary: very important pharmacogene information for CYP3A5 Jatinder Lambaa, Joan M. Hebertb, Erin G. Schuetzd, Teri E. Kleinb, and Russ B. Altmanc aDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, Institute of Human Genetics, University of Minnesota, Minnesota bDepartment of Genetics, Stanford University, Stanford, California cDepartments of Genetics, Bioengineering, Stanford University, Stanford, California dDepartment of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, USA Keywords CYP3A5; CYP3A5*2; CYP3A5*3; CYP3A5*6; CYP3A5*7; pharmacogenomics; rs10264272; rs28365083; rs76293380; rs776746 Introduction The aim of a PharmGKB VIP summary is to provide a simple overview of a gene with respect to drug effects. In some cases, there may be extensive evidence of variants that have known pharmacogenomic relevance, whereas in other cases, the summary may serve to highlight the gaps in knowledge where further study would aid the field. This summary points to the PharmGKB website to provide an interactive version that is linked to annotated publications and to related drugs, diseases, and pathways. The human CYP3A subfamily, CYP3A4, CYP3A5, CYP3A7, and CYP3A43, is one of the most versatile of the biotransformation systems that facilitate the elimination of drugs (37% of the 200 most frequently prescribed drugs in the US [1]). Together, CYP3A4 and CYP3A5 account for ~30% of hepatic cytochrome P450, and approximately half of the medications that are oxidatively metabolized by P450 are CYP3A substrates.
    [Show full text]
  • Front Matter (PDF)
    zdd0070800SPC1.qxd 6/12/08 12:50 PM Page 1 Volume 36 ■ Number 7 ■ July 2008 ■ ISSN 0090-9556 Drug Metabolism and disposition Differentiated Differentiated Differentiated HepaRG HepaRG HepaRG Gene Human Differentiated cultured w/o cultured w/o cultured w/o symbol Name hepatocytes HepaRG DMSO for 1d DMSO for 5d DMSO for 14d CYP1A1 CYP1A1 CYP1A2 CYP1A2 CYP2A6 CYP2A6 CYP2B6 CYP2B6 CYP2C8 CYP2C8 CYP2C9 CYP2C9 CYP2C19 CYP2C19 CYP2D6 CYP2D6 CYP2E1 CYP2E1 CYP3A4 CYP3A4 CYP3A7 CYP3A7 CYP7A1 CYP7A1 GSTA1 GSTA1 SULT2A1 SULT2A1 UGT2B7 UGT2B7 SLCO2B1 OATP2B1 SLCO1B1 OATP1B1 SLCO1B3 OATP1B3 SLC22A7 SLC22A7 SLC22A1 SLC22A1 SLC10A1 SLC10A1 SLC15A1 SLC15A1 ABCB1 MDR1 ABCB4 MDR3 ABCC1 MRP1 ABCC2 MRP2 ABCC3 MRP3 ABCB11 BSEP ABCG2 BCRP NR1I2 PXR NR1I3 CAR AHR AhR NR1H4 FXR RXRA RXRα RXRB RXRβ HNF4A HNF4α CEBPA CEBPα CEBPB CEBPβ AFP Alpha fetoprotein ALB Albumin DBP D site-binding protein G6PC3 Glucose-6-phosphatase GATA4 Transcription factor GATA-4 TTR Transthyretin N.D. 0.0001-0.01 0.01-0.2 0.2-0.8 0.8-1.2 1.2-2 2.0-5.0 >5.0 A Publication of the American Society for Pharmacology and Experimental Therapeutics Drug Metabolism and Disposition Volume 36 ■ Number 7 ■ July 2008 Pages 1189 – 1452 zdd0070800SPC1.qxd 6/12/08 12:50 PM Page 2 DRUG METABOLISM AND DISPOSITION A Publication of the American Society for Pharmacology and Experimental Therapeutics Founded by Kenneth C. Leibman—1973 Eric F. Johnson, Editor ASSOCIATE EDITORS Stephen D. Hall, Laurence S. Kaminsky, Russell A. Prough, John D. Schuetz, Jeffrey C. Stevens, Kenneth E. Thummel, Donald J. Tweedie, Steven A.
    [Show full text]
  • Comprehensive Bioinformatics Analysis of Lncrnas in Gastric Cancer
    ONCOLOGY LETTERS 17: 1279-1291, 2019 Comprehensive bioinformatics analysis of lncRNAs in gastric cancer DONGDONG QI1, QIANG WANG2, MEIQING WU3 and XIONG ZHANG4 1Department of Clinical Laboratory, Hulunbuir Mental Health Center; 2Department of General Surgery; 3Dermatological Department, Inner Mongolia Forestry General Hospital; 4Hulunbuir Mental Health Center, Hulunbuir, Inner Mongolia 022150, P.R. China Received November 26, 2017; Accepted July 3, 2018 DOI: 10.3892/ol.2018.9707 Abstract. Long non-coding RNAs (lncRNAs) have been of tumor cells and developing into the terminal stage of cancer. generally considered to serve important roles in various Nowadays, lack of efficient biomarkers for early diagnosis, types of cancer, including gastric cancer. However, a comprehensive treatment and cancer monitoring has been comprehensive understanding of lncRNAs in gastric cancer considered as one of the main obstacles for better prognosis requires further study. The present study performed an of gastric cancer (2). As a result, it is of great importance to in-depth study revealed 50 differently expressed lncRNAs. further explore the molecular mechanism during the occur- The changed cellular pathways and biological process in rence and development of gastric cancer, hoping to provide gastric cancer were determined. To further confirm the func- new strategy for diagnosis, prognosis and treatment (3). tions of the differently expressed lncRNAs, co-expression During the recent years, non-coding RNAs have been networks were constructed between the lncRNAs and generally concerned because of their diverse roles in the mRNA; this lead to the identification of 6 modules, which post-transcriptional regulation and they are considered to have participated in various cellular pathways.
    [Show full text]
  • Recent Advances in P450 Research
    The Pharmacogenomics Journal (2001) 1, 178–186 2001 Nature Publishing Group All rights reserved 1470-269X/01 $15.00 www.nature.com/tpj REVIEW Recent advances in P450 research JL Raucy1,2 ABSTRACT SW Allen1,2 P450 enzymes comprise a superfamily of heme-containing proteins that cata- lyze oxidative metabolism of structurally diverse chemicals. Over the past few 1La Jolla Institute for Molecular Medicine, San years, there has been significant progress in P450 research on many fronts Diego, CA 92121, USA; 2Puracyp Inc, San and the information gained is currently being applied to both drug develop- Diego, CA 92121, USA ment and clinical practice. Recently, a major accomplishment occurred when the structure of a mammalian P450 was determined by crystallography. Correspondence: Results from these studies will have a major impact on understanding struc- JL Raucy,La Jolla Institute for Molecular Medicine,4570 Executive Dr,Suite 208, ture-activity relationships of P450 enzymes and promote prediction of drug San Diego,CA 92121,USA interactions. In addition, new technologies have facilitated the identification Tel: +1 858 587 8788 ext 116 of several new P450 alleles. This information will profoundly affect our under- Fax: +1 858 587 6742 E-mail: jraucyȰljimm.org standing of the causes attributed to interindividual variations in drug responses and link these differences to efficacy or toxicity of many thera- peutic agents. Finally, the recent accomplishments towards constructing P450 null animals have afforded determination of the role of these enzymes in toxicity. Moreover, advances have been made towards the construction of humanized transgenic animals and plants. Overall, the outcome of recent developments in the P450 arena will be safer and more efficient drug ther- apies.
    [Show full text]